Postexposure prophylaxis with nirmatrelvir-ritonavir does not cut COVID-19 infection
Postexposure prophylaxis with nirmatrelvir-ritonavir for five or 10 days does not reduce the risk for symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, according to a study published in the ...
Jul 18, 2024
0
1